| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Feb 2026 | 10 Feb 2026 |
| Quarterly Results. Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31, 2025, and any other business, if any. Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve and take on record the Un-Audited standalone and consolidated Financial Results of the Company for the quarter ended December 31, 2025 and any other business with the permission of the Chair. With reference to the earlier announcement dated February 10, 2026, pursuant to the provisions of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, this is to inform you that, due to unavoidable circumstances, the Meeting of Board of Directors which was scheduled to be held on Friday, February 13, 2026 is now postponed and re-scheduled on Saturday, February 14, 2026 (As per BSE Announcement dated on: 11.02.2026) Pursuant to Regulations 30 and 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), we hereby inform you that the Board of Directors of Gujarat Kidney and Super Speciality Limited (the Company) at its meeting held today, i.e. Saturday, February 14, 2026, inter alia, considered and approved the following matters: 1. Approval of Unaudited Financial Result The Board approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025, along with the Limited Review Report issued by the Statutory Auditors. Copies of the following documents are enclosed below. a) Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025; and b) Limited Review Report of the Statutory Auditors thereon and any other business matters. (As Per BSE Announcement Dated on: 14/02/2026) | ||
| Board Meeting | 5 Feb 2026 | 5 Feb 2026 |
| Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Thursday, 5th February, 2026 (which commenced at 3:30 p.m. and concluded at 4:30 .p.m.), inter alia, has approved the following:- 1) APPROVAL FOR TO MAKE INVESTMENT IN PATEL PHARMACY. 2) APPROVAL FOR TO MAKE INVESTMENT IN PATEL MULTISPECIALITY HOSPITAL AND ICU. | ||
| Board Meeting | 6 Jan 2026 | 6 Jan 2026 |
| Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Tuesday, 6th January, 2025 (which commenced at 5:00 p.m. and concluded at 6:00 .p.m.), inter alia, has approved the following:- 1) APPROVAL FOR AQUIRE REMAINING 49% SHARES OF M/S. HARMONY MEDICARE PRIVATE LIMITED AND TO MAKE THEM AS WHOLLY OWNED SUBSIDIARY COMPANY. 2) ACCORDING TO ACQUISITION AGREEMENT AND THE ACQUISITION AGREEMENT-II AND OBJECT OF THE ISSUE OF INITIAL PUBLIC OFFERING, THE BOARD OF DIRECTORS APPROVED TO MAKE PART PAYMENT OF RS. 1,240 LAKHS AS PURCHASE CONSIDERATION FOR THE ALREADY ACQUIRED ASHWINI MEDICAL CENTRE | ||
| Board Meeting | 2 Jan 2026 | 2 Jan 2026 |
| Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Friday, 2nd January, 2025 (which commenced at 10:00 a.m. and concluded at 11:00 a.m.), inter alia, has approved the following:- 1) APPROVAL FOR ACQUISITION OF 100% EQUITY STAKE IN PAREKHS HOSPITAL PRIVATE LIMITED AND FOR EXECUTION OF SHARE PURCHASE AGREEMENT WITH THE PROMOTER GROUP OF PAREKHS HOSPITAL PRIVATE LIMITED : The Board of Directors has approved the purchase / acquisition of 100% Equity Stake in Parekhs Hospital Private Limited to make that Company as a wholly owned subsidiary of the Company. | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
